NLRP3 and Alzheimer disease: Therefore, we hypothesize that suppressing pro-inflammatory cytokine signaling (e.g., that of NLRP3 inflammasome–IL-1β) relieves its inhibition of the signaling pathways of other cytokines (e.g., IL-33) and hence promotes beneficial microglial activation in AD (Fig. 1d).